

ASX/Media Release

16 December 2019

Interview: Botanix Corporate Update

Philadelphia PA and Sydney Australia, 16 December 2019: Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) is pleased to present a Finance News Network interview with Founder and Consultant, Matt Callahan. The interview addresses the Company’s corporate plans following the release of Phase 2 acne study data, as well as Botanix’s plans for further clinical studies including the Phase 2 atopic dermatitis study and outlook over the next 6 months.

The interview can be found on the Botanix website – under “VIDEOS”:

<https://www.botanixpharma.com/investors/>

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company’s focus is the development of safe and effective topical treatments for serious skin diseases, leveraging the unique anti-inflammatory, immune modulating and antimicrobial properties of synthetic cannabidiol. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases.

The Company has announced data from its Phase 2 acne patient study and is preparing for the end of Phase 2 meeting with the FDA. A Phase 2 patient study in atopic dermatitis is now fully recruited with data planned for 1Q CY2020 and its new Phase 1b rosacea study recently received ethics approval. The Company has also successfully completed a mechanism of action study for synthetic cannabidiol in skin disease, with positive data announced in June 2019 and is developing a pipeline of product candidates that leverages the antimicrobial properties of cannabidiol, with first products planned to enter the clinic in Q1 CY2020.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital
P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Haley Chartres
Hales² Communications
P: +61 423 139 163

haley@h-squared.com.au

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.